Cargando…

Role of VEGFA gene polymorphisms in colorectal cancer patients who treated with bevacizumab

OBJECTIVES: This study aimed to explore the effects of vascular endothelial growth factor A (VEGFA) gene polymorphisms (rs699947 and rs833061) on Bevacizumab (BEV) treatment in colorectal cancer (CRC) patients. METHODS: 125 CRC cases receiving BEV plus FOLFIRI treatment were recruited in this study....

Descripción completa

Detalles Bibliográficos
Autores principales:	Cui, Wei, Li, Feng, Yuan, Qiang, Chen, Gang, Chen, Cailing, Yu, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739652/ https://www.ncbi.nlm.nih.gov/pubmed/29285265 http://dx.doi.org/10.18632/oncotarget.22295

Ejemplares similares

Impact of VEGFA polymorphisms on glioma risk in Chinese
por: Zhao, Peng, et al.
Publicado: (2017)

Bevacizumab Induces Upregulation of Keratin 3 and VEGFA in Human Limbal Epithelial Cells in Vitro
por: Notara, Maria, et al.
Publicado: (2019)

The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab
por: Zhang, Shu-Dong, et al.
Publicado: (2015)

Polymorphisms in the VEGFA and VEGFR-2 genes and neovascular age-related macular degeneration
por: Fang, Amy M., et al.
Publicado: (2009)

Association of VEGFA and IL1β gene polymorphisms with preeclampsia in Sudanese women
por: Hamid, Hameed M., et al.
Publicado: (2020)

Lack of association between the VEGFA gene polymorphisms and preterm birth in Korean women
por: Shi, Yue, et al.
Publicado: (2023)

Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies
por: Takahashi, Naoki, et al.
Publicado: (2016)

High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma
por: Alves, Bárbara, et al.
Publicado: (2023)

Association of Genetic Polymorphisms on VEGFA and VEGFR2 With Risk of Coronary Heart Disease
por: Liu, Doxing, et al.
Publicado: (2016)

The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis
por: Dai, Jiali, et al.
Publicado: (2019)

UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI
por: Hsieh, Yi-Chien, et al.
Publicado: (2021)

Association of VEGFA polymorphisms with susceptibility and clinical outcome of hepatocellular carcinoma in a Chinese Han population
por: Liu, Fei, et al.
Publicado: (2017)

Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy
por: Peng, Yu, et al.
Publicado: (2018)

The role of pericytes on the efficacy of bevacizumab in colorectal cancer
por: BESLER, Merve, et al.
Publicado: (2022)

MicroRNA gene polymorphisms and the risk of colorectal cancer
por: Rong, Guo-Qiang, et al.
Publicado: (2017)

Two polymorphisms (rs699947, rs2010963) in the VEGFA gene and diabetic retinopathy: an updated meta-analysis
por: Lu, Yan, et al.
Publicado: (2013)

Association of common polymorphisms in the VEGFA and SIRT1 genes with type 2 diabetes-related traits in Mexicans
por: Totomoch-Serra, Armando, et al.
Publicado: (2018)

Machine Learning Approaches for Predicting Bisphosphonate-Related Osteonecrosis in Women with Osteoporosis Using VEGFA Gene Polymorphisms
por: Kim, Jin-Woo, et al.
Publicado: (2021)

Targeted therapies in the management of colorectal carcinoma: role of bevacizumab
por: Puthillath, Ajithkumar, et al.
Publicado: (2009)

Clinical analysis of bevacizumab targeting therapy in treating early colorectal carcinoma after operation
por: Li, Tie-Ling, et al.
Publicado: (2017)

Highlighted role of VEGFA in follow up of celiac disease
por: Rezaei-Tavirani, Sina, et al.
Publicado: (2019)

Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab
por: Epistolio, Samantha, et al.
Publicado: (2021)

miR-150-5p suppresses tumor progression by targeting VEGFA in colorectal cancer
por: Chen, Xiaoxiang, et al.
Publicado: (2018)

Association of Genetic Polymorphisms on VEGFA and VEGFR2 With Risk of Coronary Heart Disease: Erratum
Publicado: (2016)

Two faces of bivalent domain regulate VEGFA responsiveness and angiogenesis
por: Chen, Jiahuan, et al.
Publicado: (2020)

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
por: Rosen, Lee S., et al.
Publicado: (2017)

Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis
por: Cai, Jun, et al.
Publicado: (2013)

Case report: Changes in serum bevacizumab concentration in a hemodialysis patient with unresectable colorectal cancer treated with FOLFIRI plus bevacizumab
por: Tanaka, Toshimitsu, et al.
Publicado: (2022)

Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)
por: Jin, Ran, et al.
Publicado: (2023)

Perfusion imaging of colorectal liver metastases treated with bevacizumab and stereotactic body radiotherapy
por: Detsky, Jay S., et al.
Publicado: (2018)

CT texture analysis as a prognostic marker in metastatic colorectal cancer patients treated with bevacizumab
por: Chen, Shih-Hsin, et al.
Publicado: (2015)

Knockdown of PPARδ Induces VEGFA-Mediated Angiogenesis via Interaction With ERO1A in Human Colorectal Cancer
por: Luo, Wenjun, et al.
Publicado: (2021)

The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]
por: Clarke, Stephen John, et al.
Publicado: (2020)

Comparison of UGT1A1 Polymorphism as Guidance of Irinotecan Dose Escalation in RAS Wild-Type Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line Therapy
por: Tsai, Hsiang-Lin, et al.
Publicado: (2022)

VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer
por: Terme, Magali, et al.
Publicado: (2013)

Inhibition of VEGFA Increases the Sensitivity of Ovarian Cancer Cells to Chemotherapy by Suppressing VEGFA-Mediated Autophagy
por: Li, Xia, et al.
Publicado: (2020)

Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting()()
por: Lu, Chien-Yu, et al.
Publicado: (2015)

Correction for: miR-150-5p suppresses tumor progression by targeting VEGFA in colorectal cancer
por: Chen, Xiaoxiang, et al.
Publicado: (2021)

METTL3 dual regulation of the stability of LINC00662 and VEGFA RNAs promotes colorectal cancer angiogenesis
por: Zhang, Guoying, et al.
Publicado: (2022)

FOLFIRI(®) and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms
por: Bécouarn, Yves, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_25tar3fg26tud1nubo3dk0r3q1